«The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes». Lancet, vol. 368, 9548, 11-2006, pàg. 1696–705. DOI: 10.1016/S0140-6736(06)69705-5. PMID: 17098089.
«Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis». JAMA, vol. 298, 2, 7-2007, pàg. 194–206. DOI: 10.1001/jama.298.2.194. PMID: 17622601.
nih.gov
ncbi.nlm.nih.gov
«The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes». Lancet, vol. 368, 9548, 11-2006, pàg. 1696–705. DOI: 10.1016/S0140-6736(06)69705-5. PMID: 17098089.
«Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis». JAMA, vol. 298, 2, 7-2007, pàg. 194–206. DOI: 10.1001/jama.298.2.194. PMID: 17622601.
worldcat.org
Rang and Dale's Pharmacology. 8th. United Kingdom: Elsevier Churchill Livingstone, 2016, p. 385. ISBN 9780702053627. OCLC903083639.